WeVote
Log In

Bill

Bill

H 4489

An Act to ensure affordable prescription medications through accountability standards

194th Legislature (2025-2026) Introduced by James Arena-DeRosa and 10 co-sponsors

Massachusetts bill establishes pharmaceutical pricing accountability standards and state oversight requiring manufacturers and insurers to justify price increases and demonstrate medication affordability.

Reporting date extended to Friday, July 31, 2026
0
WeVote Research Nonpartisan
Bill Summary · H 4489

Legislative bill overview

H 4489 establishes accountability standards for prescription medication pricing in Massachusetts, requiring pharmaceutical manufacturers and insurers to justify price increases and demonstrate affordability measures. The bill creates mechanisms for state oversight of drug pricing practices and aims to improve transparency in the pharmaceutical supply chain.

Why is this important

Prescription drug costs remain a major burden for Massachusetts residents, with many forgoing or rationing medications due to expense. This bill attempts to address that through direct state intervention in pharmaceutical pricing, which could affect medication accessibility and healthcare costs for thousands of residents while potentially influencing pharmaceutical company operations in the state.

Potential points of contention

  • Pharmaceutical industry opposition: Manufacturers may argue price controls or excessive documentation requirements discourage investment in drug development or reduce Massachusetts market availability
  • Definition and enforcement of "affordability": Unclear standards for what constitutes affordable pricing could create legal challenges or inconsistent application across drug types
  • Interstate commerce concerns: States have limited authority to regulate national pharmaceutical markets; federal preemption challenges are possible
  • Insurance company compliance costs: Increased reporting and accountability requirements may increase administrative costs that could be passed to consumers through premiums
  • Scope ambiguity: The bill's relationship to H 1092 (the draft it references) is unclear from the provided information

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.